Yeruusaalem, 20 January, 2026 (TPS-IL) — Shirkadda CannaLean Biotechs ee Israa’iil ayaa ku dhawaaqday inay si guul leh u dhammaystirtay daraasaddii ugu horreysay ee dadka lagu sameeyay ee CLC-01, oo ah daaweyn cusub oo afka laga qaato oo ah cannabidiol–chitosan (CBD–CHT) oo loogu talagalay kolesteroolka sare ee LDL. Daraasaddan oo socotay 12 toddobaad, oo lagu sameeyay iyada oo la kaashanayo Adeegyada Caafimaadka Kalalit, oo ah ururka ugu weyn ee daryeelka caafimaadka Israa’iil, ayaa muujisay in CLC-01 si wanaagsan loo dulqaatay isla markaana ay keentay celcelis ahaan 28% dhimis heerarka LDL ee ka qaybgalayaasha.
“Natiijooyinkan waxay xaqiijinayaan habkayaga,” ayuu yiri Madaxa Sayniska ee Moshe Mittelman. CannaLean waxay qorsheyneysaa inay CLC-01 u gudbiso daraasado ballaaran oo caafimaad, iyadoo ujeedadu tahay in la siiyo daaweyn badbaado leh oo la heli karo bukaanada aan u dulqaadan karin statins, iyadoo sidoo kale la sahaminayo suuq-geyn caalami ah oo ballaaran.